A study published in Nature Metabolism has raised questions about glucosamine Alzheimer’s progression risk, finding that people with mild cognitive impairment who took the popular joint supplement were 25% more likely to progress to dementia than those who did not. The research comes from the University of Florida, and the authors are clear that association is not causation, but they say the signal is strong enough to warrant a controlled human clinical trial.
What the health records showed
The team, led by Ramon Sun, director of the Centre for Advanced Spatial Biomolecule Research and associate director for innovation of UF’s McKnight Brain Institute, used an artificial intelligence tool to analyse deidentified patient records from the UF health system collected between 2012 and 2024. According to 2 Minute Medicine, the study was published on 9 June 2026. Working with Yi Guo and Jiang Bian, the researchers focused on patients diagnosed with Alzheimer’s disease and related dementias (ADRD) or with mild cognitive impairment (MCI), the latter describing measurable problems with memory or thinking that do not necessarily disrupt everyday life.
In both groups, 8% of patients reported using glucosamine: 1,896 people with ADRD and 2,750 with MCI. After accounting for age, sex and demographics, glucosamine use in the MCI group was associated with a 25% higher likelihood of progressing to dementia. Among people who already had ADRD, glucosamine use was also associated with a 25% higher mortality risk. That mortality association was not observed in the MCI group, which the researchers say suggests glucosamine may have a stronger effect once dementia is already established.
The 8% prevalence figure matters beyond the UF dataset. Nature Metabolism notes that it suggests potentially over 1 million patients may be unknowingly worsening their disease progression through glucosamine supplementation. Sun put it plainly: ‘A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.’
The study’s co-author Matt Gentry, chair of UF’s Department of Biochemistry and Molecular Biology, was careful about what the data can and cannot say. ‘While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention,’ he said.
A biological mechanism for glucosamine Alzheimer’s progression
The health record findings were accompanied by laboratory work aimed at identifying a plausible biological explanation. The researchers examined a process in which sugar structures are attached to proteins, a normal part of cell biology that appears to become excessively active in Alzheimer’s disease. Glucosamine, a sugar-related molecule that can cross the blood-brain barrier, can enter the biochemical pathways that construct and attach these sugar structures.
Experiments in genetically modified mice found that glucosamine significantly increased this sugar-attachment process. Treated mice also showed worse deficits in social memory compared with untreated animals. When researchers suppressed the sugar-attachment pathway chemically, memory performance improved, suggesting the mechanism was doing something to the animals’ cognition, not merely occurring alongside it.
Human tissue told a consistent story. Brain specimens from people with Alzheimer’s disease, supplied by the UF Neuromedicine Brain and Tissue Bank and examined with Stefan Prokop, showed significantly more sugar attachment than tissue from people without the disease. Gentry described the implication: ‘What we found in Alzheimer’s is that this sugar-tagging system appears to be overactive. The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it.’
Sun connected this to the broader question of how Alzheimer’s develops. ‘Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles,’ he said. Much research has traditionally centred on amyloid beta plaques and tau tangles, but this work points to metabolic disruption as a parallel line of inquiry.
The study does not establish that people with cognitive impairment should stop taking glucosamine. The researchers are explicit that the retrospective, observational design cannot rule out other differences between supplement users and non-users that might explain the association. The glucosamine Alzheimer’s progression question, they say, now requires a prospective, controlled human clinical trial to determine whether the supplement directly accelerates disease and, if so, which patients face the greatest risk.
